Evidence from the SPRINTER clinical trial showed that SNG001, an inhalable immunity-boosting drug, helped reduce fatigue, loss of smell, and other symptoms associated with Long COVID. Although further research is needed, the authors of the study are hopeful that this treatment can soon help many more Long COVID patients find relief.*

What is SNG001?

SNG001 contains interferon beta, an antiviral protein that’s produced in the lungs during viral lung infections. Some people, such as older adults and individuals with certain chronic illnesses, can be deficient in interferon beta. Since many viruses inhibit interferon beta, administering the inhalable drug can reduce inflammation and help protect lung cells against potentially harmful viruses, including coronaviruses like SARS-CoV-2. 

In the SPRINTER trial, scientists from Synairgen Research Ltd. investigated whether or not SNG001 could restore interferon beta levels in the lungs, and in turn, reduce a patient’s time in the hospital, as well as recovery time.

What did the research show?

For the SPRINTER trial, 623 hospitalized COVID-19 patients were treated and observed. Patients were randomly assigned to one of two groups, with 314 receiving the inhaled SNG001 treatment and 304 receiving a placebo for two weeks.

While the treatment did not shorten patients’ times in the hospital or recovery, it did have promising long-term effects.

After 60 and 90 days, researchers recorded patients’ Long COVID symptoms, as well as anxiety levels, fatigue, and other overall health measures.

Compared to the group that received the placebo treatment, those who received SNG001 experienced an all-over lower risk of Long COVID, including:

• 35% lower risk of fatigue,  
• 28% lower risk of shortness of breath, and 
• 61% lower risk of loss of smell or taste.

Potential Long COVID treatment

Authors of the study say that while SNG001 did not meet their initial outcome measure of shortening participants’ time in the hospital, it may be helpful in treating some of the debilitating symptoms associated with Long COVID. They add that continued research into SNG001’s effects on COVID-19 and Long COVID is needed.

*Cosdon, N. (2022, October 21). SNG001 Fails Primary Endpoints, But May Alleviate Long COVID Symptoms. Contagion Live. https://www.contagionlive.com/view/sng001-fails-primary-endpoints-but-may-alleviate-long-covid-symptoms